Effect of Alfacalcidol on Inflammatory markers and T Cell Subsets in Elderly with Frailty Syndrome: a Double Blind Randomized Controlled Trial
Keywords:
Alphacalcidol, inflammation, T cell, elderly, frailtyAbstract
Background: Alphacalcidol, a vitamin D analog, shows immune regulatory potency as it works on the macrophage and T cell to control inflammation and T cell dysregulation in elderly. None has been known about its effect on elderly with various states of frailty syndrome, which have different level of chronic low grade inflammation. This study aimed to determine the effect of alphacalcidol on inflammatory cytokines (IL-6, IL-10, g-IFN ) and T cell subsets (CD4/CD8 ratio and CD8+ CD28-) of elderly with various stages of frailty syndrome. Methods: from January to July 2017, a double blind randomized controlled trial (RCT) with allocation concealment, involving 110 elderly subjects from Geriatric Outpatient Clinic Cipto Mangunkusumo Hospital Jakarta, was conducted to measure the effect of 0.5 mcg alphacalcidol administration for 90 days to inflammatory cytokines (IL-6, IL-10, g-IFN) from PBMC culture supernatant, as well as CD4/CD8 and CD8+CD28- percentage using flow cytometry. Statistical analysis using SPSS version 20 was performed with t-test to measure mean difference. Results: of 110 subjects involved in the RCT consisting of 27 fit, 27 pre-frail and 56 frail elderly, 25(OH)D serum level was found to be as low as 25.59 (12.2) ng/ml in alphacalcidol group and 28.27 (10.4) ng/ml in placebo group. Alphacalcidol did not decrease IL-6 (p=0.4) and g- IFN (p=0.001), but it increased IL-10 (p=0,005) and decreased IL6/IL10 ratio (p=0.008). Alphacalcidol increased CD4/CD8 ratio from 2.68 (SD 2.45) to 3.2 (SD 2.9); p=0.001 and decreased CD8+ CD28- percentage from 5.1 (SD 3.96) to 2.5 (1.5); p<0.001. Sub group analysis showed similar patterns in all frailty states. Conclusion: Alphacalcidol improves immune senescence by acting as anti-inflammatory agent through increased IL-10 and decreased IL6/IL-10 ratio and also improves cellular immunity through increased CD4/CD8 ratio and decreased CD8+ CD28- subset in elderly. This effect is not influenced by frailty state.References
Fried LP, Hadley EC, Walston JD, et al. Frailty in older adults: evidence of a phenotype. J Gerontol A Biol Sci Med Sci. 2001;56A:M1-M11.
Fried LP, Hadley EC, Walston JD, et al. From bedside to bench: research agenda for frailty. Sci Aging Knowledge Environ. 2005;e 24.
Blasimme A. Physical frailty, sarcopenia and the enablement of autonomy: philosophical issues in geriatric medicine. Aging Clin Exp Res. 2017;29(1):43-8.
Strandberg TE, Pitkala KH. Frailty in elderly people. Lancet. 2007;369:1328-9.
Li H, Manwani B, Leng S. Frailty, inflammation and immunity. Aging Dis. 2011;2(6):466-73.
Fougere B, Boulanger E, Nourhashemi F. Chronic Inflammation: Accelerator of Biological Aging. J Gerontol A Bio Sci Med Sci. Sep 1;72(9):1218-25.
Cantorna M, Snyder L. Vitamin D and 1,25(OH)2D Regulation of T cells. Nutrients. 2015;7(4):2011-3021.
Kearns M, Alvarez J, Seidel N, Tangpricha V. The impact of vitamin D on infectious disease: a systematic review of controlled trials. Am J Med Sci. 2015; 349(3):245-62.
Calton EK, Keane KN, Newsholme P. The impact of cholecalciferol supplementation on the systemic inflammatory profile: a systematic review and meta analysis of randomized controlled trials. Eur J of Clin Nutr. 2017;71:931-43.
Ojaimi. Vitamin D deficiency impact on expression of toll like receptor 2 and cytokine profile: a pilot study. J Translational Med. 2013;11:176.
Yusupov E, Li-Ng M, Pollack S, Yeh JK, Mikhail M, Aloia JF. Vitamin D and serum cytokune s in a randomized controlled trial. Int J Endocrinol 2010;2010. Pii: 305054.
Mahon BD. Cytokine profile in patients with multiple sclerosis following vitamin D supplementation. J Neuroimmunol. 2003;134:128-32
Schleithoff S, Zittermann A, Tenderich G, Berthold H. Vitamin D supplementation improves cytokine profiles in patients with congestive heart failure: a double blind randomized placebo controlled trial. Am J Clin Nutr. 2006;83:754-9.
Strioga M, Pasukoniene V, Characiejus D. CD8+ CD28- and CD8+ CD57+ T cells and their role in health and disease. Immunol. 2011;134(1):17-32.
Downloads
Published
How to Cite
Issue
Section
License
Copyright
The authors who publish in this journal agree to the following requirements:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors can enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) before and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work. (See The Effect of Open Access)
Privacy Statement
The names and email addresses entered in this journal site will be used exclusively for the stated purposes of this journal and will not be made available for any other purpose or to any other party.
